Norges Bank’s PTC Therapeutics PTCT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-53,807
| Closed | -$4.09M | – | 1058 |
|
|
2025
Q4 | $4.09M | Buy |
+53,807
| New | +$3.91M | ﹤0.01% | 1402 |
|
|
2024
Q3 | – | Sell |
-15,100
| Closed | -$462K | – | 1936 |
|
|
2024
Q2 | $462K | Buy |
+15,100
| New | +$489K | ﹤0.01% | 1884 |
|
|
2024
Q1 | – | Sell |
-546,375
| Closed | -$15.1M | – | 1951 |
|
|
2023
Q4 | $15.1M | Buy |
546,375
+12,500
| +2% | +$286K | ﹤0.01% | 1349 |
|
|
2023
Q3 | $12M | Buy |
533,875
+3,800
| +0.7% | +$141K | ﹤0.01% | 1400 |
|
|
2023
Q2 | $21.6M | Sell |
530,075
-40,376
| -7% | -$1.98M | ﹤0.01% | 1224 |
|
|
2023
Q1 | $27.6M | Sell |
570,451
-73,706
| -11% | -$3.37M | 0.01% | 1119 |
|
|
2022
Q4 | $24.6M | Sell |
644,157
-47,917
| -7% | -$1.99M | 0.01% | 1160 |
|
|
2022
Q3 | $34.7M | Buy |
692,074
+11,146
| +2% | +$546K | 0.01% | 933 |
|
|
2022
Q2 | $27.3M | Buy |
680,928
+118,112
| +21% | +$4.14M | 0.01% | 1089 |
|
|
2022
Q1 | $21M | Buy |
562,816
+148,190
| +36% | +$5.71M | ﹤0.01% | 1381 |
|
|
2021
Q4 | $16.5M | Sell |
414,626
-134,514
| -24% | -$5.15M | ﹤0.01% | 1568 |
|
|
2021
Q3 | $20.4M | Buy |
549,140
+29,728
| +6% | +$1.22M | ﹤0.01% | 1473 |
|
|
2021
Q2 | $22M | Buy |
519,412
+73,666
| +17% | +$3.16M | ﹤0.01% | 1482 |
|
|
2021
Q1 | $21.1M | Sell |
445,746
-108,544
| -20% | -$6.45M | ﹤0.01% | 1516 |
|
|
2020
Q4 | $33.8M | Buy |
554,290
+47,161
| +9% | +$2.78M | 0.01% | 1234 |
|
|
2020
Q3 | $23.7M | Sell |
507,129
-66,754
| -12% | -$3.29M | 0.01% | 1299 |
|
|
2020
Q2 | $29.1M | Sell |
573,883
-98,629
| -15% | -$4.85M | 0.01% | 1193 |
|
|
2020
Q1 | $30M | Buy |
672,512
+13,320
| +2% | +$671K | 0.01% | 978 |
|
|
2019
Q4 | $31.7M | Buy |
659,192
+24,875
| +4% | +$1.06M | 0.01% | 1225 |
|
|
2019
Q3 | $21.5M | Buy |
634,317
+19,824
| +3% | +$863K | 0.01% | 1442 |
|
|
2019
Q2 | $27.7M | Buy |
614,493
+506,123
| +467% | +$20M | 0.01% | 1280 |
|
|
2019
Q1 | $4.08M | Buy |
+108,370
| New | +$3.64M | ﹤0.01% | 1957 |
|
|
2016
Q4 | – | Sell |
-125,458
| Closed | -$1.68M | – | 2165 |
|
|
2016
Q3 | $1.68M | Buy |
125,458
+90,181
| +256% | +$733K | ﹤0.01% | 1997 |
|
|
2016
Q2 | $247K | Sell |
35,277
-75,014
| -68% | -$550K | ﹤0.01% | 2148 |
|
|
2016
Q1 | $710K | Hold |
110,291
| – | – | ﹤0.01% | 2109 |
|
|
2015
Q4 | $3.57M | Sell |
110,291
-67,267
| -38% | -$1.98M | ﹤0.01% | 1935 |
|
|
2015
Q3 | $4.74M | Sell |
177,558
-27,394
| -13% | -$1.17M | ﹤0.01% | 1856 |
|
|
2015
Q2 | $9.87M | Buy |
204,952
+71,068
| +53% | +$4.15M | ﹤0.01% | 1626 |
|
|
2015
Q1 | $8.15M | Buy |
+133,884
| New | +$8.17M | ﹤0.01% | 1733 |
|
Other funds holding PTCT
RI
VPM
VCM
AC
Norges Bank's PTCT Position: Q1 2026 in Review
Norges Bank sold out of PTC Therapeutics (PTCT) in Q1 2026, closing a stake of 53,807 shares — an estimated $4.09M sold.
Norges Bank first reported a position in PTCT in Q1 2015 and held it in 29 quarters. The position peaked at $34.7M in Q3 2022. 349 funds tracked by Wall St. Rank hold PTCT as of Q1 2026.
- Norges Bank reported no remaining PTC Therapeutics position as of Q1 2026 after selling out during the quarter.
- Norges Bank sold 53,807 PTC Therapeutics shares in Q1 2026, an estimated $4.09M.
- Norges Bank first reported a position in PTC Therapeutics in Q1 2015 and held it in 29 quarters.
- Norges Bank's PTC Therapeutics position peaked at $34.7M in Q3 2022.
- 349 funds tracked by Wall St. Rank held PTC Therapeutics as of Q1 2026.
Based on Norges Bank's 13F filing for Q1 2026.